Third Harmonic Bio Inc.

NASDAQ THRD

Data sourced from

and

Daily

Download Data

Third Harmonic Bio Inc. Price to Sales Ratio (P/S) on June 03, 2024: 664.69

Third Harmonic Bio Inc. Price to Sales Ratio (P/S) is 664.69 on June 03, 2024, a NA change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.

Third Harmonic Bio Inc. 52-week high Price to Sales Ratio (P/S) is 761.19 on May 21, 2024, which is 14.52% above the current Price to Sales Ratio (P/S).
Third Harmonic Bio Inc. 52-week low Price to Sales Ratio (P/S) is 575.95 on May 10, 2024, which is -13.35% below the current Price to Sales Ratio (P/S).
Third Harmonic Bio Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 667.82.

NASDAQ: THRD

Third Harmonic Bio Inc.

CEO	Ms. Natalie C. Holles
IPO Date	Sept. 14, 2022
Location	United States
Headquarters	300 Technology Square, Cambridge, MA, United States, 02139
Employees	31
Sector	Healthcare
Industry	Biotechnology

Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Key trends